Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24‐week real‐life experience

Abstract

Genital psoriasis (GenPs) has been traditionally considered a difficult to treat psoriasis area. Ixekizumab was the first biologic agent demonstrating efficacy and safety in a formal clinical trial on GenPs; however, real-life experiences are limited. To assess real-life effectiveness and safety of ixekizumab in the treatment of GenPs in a case series of patients with moderate-to-severe plaque psoriasis. Adult patients with moderate-to-severe plaque psoriasis involving the genital area received subcutaneous ixekizumab. Evaluation of disease severity, clinical symptoms, and quality of life was performed at baseline, after 4, 16, and 24 weeks of treatment. Assessment tools were: Static Physician's Global Assessment of Genitalia (sPGA-G), Psoriasis Area and Severity Index (PASI) score, Itch Numerical-Rating-Score (Itch-NRS), and Dermatology-Life-Quality-Index (DLQI). Adverse events were recorded. A total of 14 patients were treated with ixekizumab achieving consistent and significant reduction of disease and quality of life parameters, with a mean percentage reduction from baseline to week 24 of 91.4% for sPGA-G, 95.2% for PASI, 95.6% for Itch-NRS, and 93.7% for DLQI. Ixekizumab treatment was well tolerated. Ixekizumab significantly improved disease severity, itch, and quality of life with an acceptable safety profile in a real-life setting in adult patients affected by GenPs.

Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting

“…Clinical trials also showed ixekizumab efficacy in long term evaluation, and in the treatment of difficult to treat psoriasis like nails, scalp, palmoplantar, genital, and pustular psoriasis 47–51 . Promising trials' results were evaluated also by real life setting studies, which confirmed trials results and showed interesting results reached with ixekizumab treatment also in terms of PASI90 and PASI100 responses 31,52 . Furthermore, real life studies compared ixekizumab with secukinumab are both highly effective in short‐ and long‐term treatment of psoriasis, even though few differences exist concerning speed of action and long‐term effectiveness, with a faster response in term of achieving PASI75 and PASI90 for ixekizumab 54,55 .…”

“…[47][48][49][50][51] Promising trials' results were evaluated also by real life setting studies, which confirmed trials results and showed interesting results reached with ixekizumab treatment also in terms of PASI90 and PASI100 responses. 31,52 Furthermore, real life studies compared ixekizumab with secukinumab are both highly effective in short-and long-term treatment of psoriasis, even though few differences exist concerning speed of action and long-term effectiveness, with a faster response in term of achieving PASI75 and PASI90 for ixekizumab. 54,55 Brodalumab efficacy and safety profiles were evaluated in three randomized double blinded controlled trials (AMAGINE-1, AMAGINE-2 and AMAGINE-3).…”

Risankizumab for the treatment of genital psoriasis: A 1‐year, real‐world experience

“…Data collection and handling complied with applicable laws, regulations and guidance regarding patient protection, including patient privacy. D. Orsini 1 P. Frascione 2 C. Assorgi 3 A. Pacifico 1 I. Sperduti 4 L. Gargiulo 5,6 L. Ibba 5,6 M. Valenti 5,6 A. Costanzo 4,5 A. Narcisi…”

“…2 Genitals are considered a difficult-to-treat area. 4,5 Topical treatments remain the first-line choice for mild-to-moderate disease. 5 However, corticosteroids are associated with longterm adverse events, and specific data on immunomodulators or vitamin D derivatives are scant.…”

“…Systemic treatments also have a role for moderate-to-severe disease, but evidence is mostly anecdotal also for those therapies. 4,5 Risankizumab is a humanized monoclonal antibody that blocks the p19 subunit of interleukin (IL)-23, which proved effective in clinical trials and field-practice experiences. 6,7 However, specific experiences on the treatment of genital psoriasis with risankizumab are scant and have a short follow-up.…”